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ANALYSIS
Few researchers think about the carbon footprint of their trial. The Sustainable Trials Study Group 
reports that clinical trials are carbon intensive and suggests ways to make them more efficient 
Towards sustainable clinical trials
Greenhouse gases are changing the global climate, 
with serious implications for health and ecosystems.1 2 
All sectors of the economy, including the health 
 sector, must act to reduce greenhouse gas emissions.3 
High income countries need to cut emissions by about 
90% by 2030 to limit the global average increase in 
 temperature to 2°C, and thus reduce the risk of the 
most serious consequences.4
The Sustainable Trials Study Group was con-
vened by the London School of Hygiene and Tropi-
cal Medicine to find ways of reducing greenhouse 
gas emissions from clinical trials. This international 
health research institution has an extensive research 
programme on the links between environment and 
health. A sustainability group was established to 
reduce the institution’s carbon footprint, and this study 
is a product of its work.
The CRASH trial case study
We conducted a carbon audit of the Medical Research 
Council (MRC) CRASH trial (www.crash.lshtm.
ac.uk) with the Edinburgh Centre for Carbon Man-
agement (www.eccm.uk.com). The CRASH trial is 
a multicentre international trial of the effect of cor-
ticosteroids on death and disability in 10 008 adults 
with head injury.5 The trial was coordinated from the 
London School of Hygiene and Tropical Medicine, 
and patients were recruited in 49 countries over five 
years (1999-2004). The drug was made by Pfizer in the 
United States and the placebo was made in France. 
Drug and placebo were packed in Wales. Treatment 
packs were sent to London for distribution to hospitals 
around the world.
Emissions were estimated for a one year period 
(August 2003 to July 2004). We collected data on 
operational activities according to the greenhouse 
gas reporting protocol developed by the World Busi-
ness Council for Sustainable Development.5-7 This 
protocol provides a choice of three “scopes.” Scope 1 
covers direct emissions from company vehicles and 
 facilities. Scope 2 includes indirect emissions from 
energy imports and exports. Scope 3 includes other 
indirect emissions such as employees’ travel, transport 
by third parties, outsourcing of core activities, and off-
site waste disposal or management activities.
We estimated all fuel use and refrigerant loss by 
the trial coordinating centre (scope 1 emissions); fuel 
use off-site for generating electricity used by the co- 
ordinating centre (scope 2 emissions); and fuel use for 
travel (including site visits, data audits, and staff com-
muting), deliveries (delivery of drugs and placebo to 
the packing company and delivery of treatment packs 
and trial documents to hospitals), and waste disposal 
(scope 3 emissions). Energy used in preparing the trial 
treatments and other materials was excluded.
We could not calculate the energy consump-
tion of the coordination centre directly because 
other activities take place there. Instead, energy 
 consumption was assessed from typical energy con-
sumption values per square metre of air conditioned 
office space. The global warming potential (in carbon 
dioxide equivalents) of emissions of methane and 
nitrous oxides from electricity generation and travel 
were calculated using conversion factors published by 
the Intergovernmental Panel on Climate Change.8
Findings
During the one year audit period, the total emission 
of greenhouse gases related to the trial was 126 tonnes 
(carbon dioxide equivalents). This is equivalent to 
that produced in one year by 32 people on the basis 
of global per capita estimates, or six people on the 
basis of US per capita estimates (www.dti.gov.uk). If 
the audit year is representative, the entire trial was 
responsible for about 630 tonnes of carbon dioxide 
equivalents. This corresponds to about 525 round 
trip flights from London to New York for one passen-
ger. In total, 10 008 patients were recruited and there 
were 1945 primary endpoint events, corresponding to 
greenhouse gas emissions of 63 kg per participant or 
324 kg per primary endpoint event.
The coordination centre accounted for the largest 
proportion of emissions (39%, 50 tonnes), followed by 
distribution of drugs and documents (28%, 35 tonnes), 
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Carbon emissions from the trial corresponded to about 525 round trips from London to New 
York for one passenger
SummArY poINTS
Clinical trials contribute 
substantially to 
greenhouse gas emissions
The main sources are 
energy use in research 
premises and air travel
Renewable energy 
sources and more efficient 
energy use would reduce 
emissions from premises
Simplified trial designs, 
reduced bureaucracy, and 
videoconferencing would 
reduce air travel
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and travel (23%, 29 tonnes) (figure). Just over 45 of 
the 50 tonnes of carbon dioxide equivalent emissions 
associated with the coordination centre were from the 
use of electricity (table), the remainder came from the 
disposal of office waste. Most (94%) of the emissions 
related to travel were from air travel and hotel stays for 
site visits, on-site data verification, and collaborators’ 
meetings (table). Although only 22% of the air travel 
mileage was short haul, because it produces more 
greenhouse gases than long haul travel, it accounted 
for 31% of air travel emissions. Most (97%) emissions 
from the distribution of drugs and documents were 
from air freight of treatment packs and documents 
to hospitals.
Implications of the case study 
Clinical trials are energy intensive and produce 
 substantial greenhouse gas emissions. The figure of 
14 tonnes per employee each year is high compared 
with other service industries, which average around 
4-6 tonnes per employee each year (Edinburgh Centre 
for Carbon Management, personal communication, 
2007). The CRASH trial was an international trial 
and our estimates may not be representative of trials 
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in general. The trial had a simple design with no extra 
tests, the primary end point was mortality, and data 
collection was minimal. For this reason, emissions per 
primary endpoint event, arguably the best measure of 
emissions per unit of statistical information, may be 
low compared with other trials. However, the trial was 
conducted in 49 countries and the distribution of drug 
and placebo was complex, so emissions from air travel 
and distribution may be higher than for other trials.
Reducing the carbon footprint of clinical trials
Saving electricity
Our audit provides insights into how to reduce the 
 carbon intensity of clinical trials. Even though this 
was an international trial, electricity use by the trial 
coordinating centre accounted for the largest share of 
emissions. Organisations could reduce such emissions 
to zero by installing on-site renewable energy sources 
or by buying electricity from renewable energy com-
panies.9 Reductions might also be achieved by fitting 
voltage optimisation devices (which reduce power con-
sumption by around 10%) to the incoming electricity 
supply and by using energy efficient lighting—motion 
sensors and light sensitive dimming, low energy light 
bulbs, and timers to turn off appliances at night.
Making trials simpler and more efficient 
Energy use in trials could be reduced by employing 
fewer people. Reducing bureaucracy and using simple 
designs with no unnecessary data collection would be 
helpful. The bureaucracy associated with applications 
to ethics committees and other regulatory bodies has 
been highlighted by many trialists and has a big impact 
on the carbon footprint of trials.10 11 Electronic remote 
collection of data may reduce staffing levels, although 
the energy use of such technologies must be taken into 
account.
Simple designs with statistical checks for data irregu-
larities can reduce the need for on-site data verifica-
tion and reduce trial related travel.12-14 Conducting 
trials within networks of trialists may reduce training 
needs, and building local capacity for trials may be 
more energy efficient than visiting experts. Provid-
ing the infrastructure for teleconferencing and video-
conferencing could reduce travel. However, frequent 
interruptions in the electricity supply occur in many 
health facilities in poor countries. Renewable energy 
sources such as photovoltaic energy could provide a 
more stable source of electricity in such situations, with 
minimal or zero greenhouse gas emissions. The health 
research community should encourage such technolo-
gies and help pilot and evaluate their use in research.
The research community must ensure that trials 
look at questions of greatest priority using methods 
compatible with broader strategic objectives in rela-
tion to environment and health. Because emissions 
have a global effect and have the greatest impact on 
the poor, trials of global relevance should be priori-
tised.15 All new trials should be underpinned scientifi-
cally by a systematic review of the existing research.16 
Indeed, by making the best use of existing informa-
Greenhouse gas emissions in the CRASH trial 
Source of emissions Equivalent emissions of carbon dioxide (tonnes per year)
Coordinating centre
   Electricity
   Refrigerant gas losses
   Waste disposal
45.4
0.0
4.2
Business travel
   Taxi
   Air
   Train
   Hotel stays
1.0
16.3
0.5
10.9
Commuting
   Rail
   Bus
   Underground
4.7
0.9
1.0
Deliveries related to production of trial drugs
   Light goods vehicles 
   Air
0.2
5.8
Distribution of trial materials
   Light goods vehicles
   Air
0.9
33.9
Proportions of greenhouse gas emissions due to different 
activities in the CRASH trial 
Coordinating
    centre
       premises  
Distribution and deliveries
Deliveries related to
production of trial drugs
Trial
related  
travel  
Trial team commuting
39%
28%
23%
5%
5%
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tion, systematic reviews are an energy efficient way of 
answering research questions. Trial results should be 
made publicly available, as the environmental conse-
quences affect us all.
Raising awareness and commitment
Conducting carbon audits on clinical trials will not 
guarantee success in reducing emissions in the short 
term. The impact of audit in clinical environments is 
modest at best.17 However, we need to establish aware-
ness about the broader consequences of health care 
and research, and through awareness increase the pace 
of action to avert one of the most important global 
challenges of our time.18 Long term change will require 
sustained commitment by research institutions and 
funding bodies. This may have other benefits, such as 
increased pragmatism in trial designs, better choice of 
research questions, and increased likelihood that trials 
produce important results for global health.
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I could tell that we had had changeover day; the referral that last 
week would probably have read, “Funny turns—?seizures,” now gave 
a full, detailed history, the space allowed filled completely with tiny 
but scrupulously neat handwriting.
As a medical student working in the neurophysiology department 
of a busy hospital to earn some money, I took a telephone call from 
a young doctor making her first referral. She’d filled in the form but 
had a question about the process, could she come and see us? I said 
yes—we have a policy of encouraging all doctors to come and see us 
if they want to talk something over. In fact, she asked her question 
immediately, and I was able to answer her. Should she still come to 
visit us? I gave her the option of coming over whenever she had a 
minute or of putting the referral form into the internal post. The next 
day she dropped into our main office, introduced herself, handed 
in the referral form, waited while I made the appointment for her 
patient, and went cheerfully on her way.
In the meantime, I had taken a call from another foundation year 1 
doctor in a hospital about 30 miles away. It was late afternoon, and 
I could hear the note of panic in his voice. He needed to speak to 
the consultant neurophysiologist urgently. I explained that neither 
she nor her secretary was available—could I help? Obviously on 
the verge of tears, he told me that he had been given a list of tests 
to arrange and given the consultant’s name, but beyond that had no 
idea how to go about doing this. I reassured him that he was talking 
to the right person, guided him through finding and then filling in the 
referral form, and stopped another panic attack when he interpreted 
something I’d said to mean that he needed to specify individual 
nerves for testing.
Finally, I told him how to address the envelope so that it would get 
to us speedily through the internal mail system. It was only his second 
day at work in the hospital, and he was already so stressed that he was 
nearly overwhelmed.
I am uneasy that he thought he needed to talk to the consultant 
herself to arrange the tests rather than her secretary or someone else 
in the office. Had he just got the wrong end of the stick or had he 
been deliberately misled? Are there still some people who think that 
getting the F1 doctor into trouble with a consultant is fun? Many 
consultants would not be pleased to be interrupted with trivia like 
booking appointments.
In a few years time it will be me struggling to learn how to be an 
effective member of a team. Will I be lucky, like the first young 
doctor, busy but given sufficient support that I can cope with the new 
environment and its pressures—or will I end up like the second doctor, 
in a situation where I am not supported and guided appropriately, 
exhausted and demoralised by the second day?
Phyllida Roe medical student, Taunton  phyllida.roe@students.pms.ac.uk
New doctors
